| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antiretroviral treatment for children with peripartum nevirapine exposure.
|
N Engl J Med
|
2010
|
3.81
|
|
2
|
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
|
J Infect Dis
|
2007
|
3.75
|
|
3
|
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
|
PLoS One
|
2009
|
3.40
|
|
4
|
Antiretroviral therapy during pregnancy and the risk of an adverse outcome.
|
N Engl J Med
|
2002
|
3.31
|
|
5
|
Antiretroviral therapies in women after single-dose nevirapine exposure.
|
N Engl J Med
|
2010
|
3.14
|
|
6
|
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
|
N Engl J Med
|
2012
|
2.50
|
|
7
|
Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.
|
J Infect Dis
|
2011
|
2.42
|
|
8
|
Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.
|
Ann Intern Med
|
2015
|
2.13
|
|
9
|
Comparison of methods to account for implausible reporting of energy intake in epidemiologic studies.
|
Am J Epidemiol
|
2015
|
2.11
|
|
10
|
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents.
|
Lancet
|
2003
|
2.04
|
|
11
|
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
|
J Infect Dis
|
2004
|
1.98
|
|
12
|
Long-term observation of adolescents initiating HAART therapy: three-year follow-up.
|
AIDS Res Hum Retroviruses
|
2007
|
1.84
|
|
13
|
A prospective, randomized trial of clear liquids versus low-fat solid diet as the initial meal in mild acute pancreatitis.
|
Clin Gastroenterol Hepatol
|
2007
|
1.74
|
|
14
|
In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
|
AIDS
|
2007
|
1.70
|
|
15
|
An internationally generalizable risk index for mortality after one year of antiretroviral therapy.
|
AIDS
|
2013
|
1.64
|
|
16
|
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
|
J Infect Dis
|
2009
|
1.61
|
|
17
|
Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection.
|
J Acquir Immune Defic Syndr
|
2003
|
1.60
|
|
18
|
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.
|
AIDS
|
2010
|
1.54
|
|
19
|
Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection.
|
Pediatrics
|
2004
|
1.51
|
|
20
|
Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment.
|
Pediatrics
|
2006
|
1.42
|
|
21
|
Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.
|
AIDS
|
2012
|
1.39
|
|
22
|
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.
|
Antimicrob Agents Chemother
|
2004
|
1.35
|
|
23
|
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
|
AIDS
|
2012
|
1.35
|
|
24
|
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
|
Antimicrob Agents Chemother
|
2006
|
1.32
|
|
25
|
The search for data on when to start treatment for HIV infection.
|
J Infect Dis
|
2008
|
1.31
|
|
26
|
Can fluid resuscitation prevent pancreatic necrosis in severe acute pancreatitis?
|
Pancreatology
|
2002
|
1.27
|
|
27
|
Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.
|
Pediatrics
|
2010
|
1.22
|
|
28
|
Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
|
Pediatrics
|
2007
|
1.21
|
|
29
|
Vitamin D deficiency and anthropometric indicators of adiposity in school-age children: a prospective study.
|
Am J Clin Nutr
|
2010
|
1.21
|
|
30
|
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
|
Pediatr Infect Dis J
|
2009
|
1.20
|
|
31
|
Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.
|
Pediatrics
|
2008
|
1.14
|
|
32
|
Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.
|
J Acquir Immune Defic Syndr
|
2010
|
1.14
|
|
33
|
Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior.
|
J Infect Dis
|
2004
|
1.11
|
|
34
|
Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana.
|
J Acquir Immune Defic Syndr
|
2011
|
1.10
|
|
35
|
The role of social networks and support in postpartum women's depression: a multiethnic urban sample.
|
Matern Child Health J
|
2006
|
1.08
|
|
36
|
Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection.
|
J Infect Dis
|
2003
|
1.05
|
|
37
|
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
|
J Acquir Immune Defic Syndr
|
2010
|
1.04
|
|
38
|
Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis?
|
Pancreas
|
2002
|
1.04
|
|
39
|
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals.
|
J Acquir Immune Defic Syndr
|
2008
|
1.04
|
|
40
|
Differential associations of leptin with adiposity across early childhood.
|
Obesity (Silver Spring)
|
2013
|
1.03
|
|
41
|
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
|
AIDS
|
2012
|
1.03
|
|
42
|
Initial treatment of HIV infection: randomized trials with clinical end points are still needed.
|
J Infect Dis
|
2006
|
1.02
|
|
43
|
Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.
|
HIV Clin Trials
|
2013
|
0.99
|
|
44
|
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
|
Clin Infect Dis
|
2009
|
0.96
|
|
45
|
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
|
Antimicrob Agents Chemother
|
2011
|
0.96
|
|
46
|
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
|
Clin Infect Dis
|
2013
|
0.96
|
|
47
|
HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana.
|
AIDS
|
2013
|
0.94
|
|
48
|
Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
|
Arch Pediatr Adolesc Med
|
2006
|
0.94
|
|
49
|
Choline intake during pregnancy and child cognition at age 7 years.
|
Am J Epidemiol
|
2013
|
0.94
|
|
50
|
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
|
J Acquir Immune Defic Syndr
|
2002
|
0.94
|
|
51
|
Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.
|
J Acquir Immune Defic Syndr
|
2011
|
0.94
|
|
52
|
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
|
AIDS
|
2011
|
0.94
|
|
53
|
Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load.
|
J Infect Dis
|
2005
|
0.91
|
|
54
|
In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana.
|
AIDS
|
2016
|
0.90
|
|
55
|
Accelerated wound healing: multidisciplinary advances in the care of venous leg ulcers.
|
Angiology
|
2006
|
0.90
|
|
56
|
Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients.
|
Stat Med
|
2010
|
0.89
|
|
57
|
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
|
Pediatr Infect Dis J
|
2014
|
0.88
|
|
58
|
The impact of psoriasis on pregnancy outcomes.
|
J Invest Dermatol
|
2011
|
0.88
|
|
59
|
Within- and between-child variation in repeated urinary pesticide metabolite measurements over a 1-year period.
|
Environ Health Perspect
|
2013
|
0.88
|
|
60
|
Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy.
|
Pediatr Infect Dis J
|
2010
|
0.87
|
|
61
|
The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219).
|
Pediatrics
|
2002
|
0.87
|
|
62
|
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.
|
J Clin Microbiol
|
2002
|
0.87
|
|
63
|
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
|
J Infect Dis
|
2014
|
0.86
|
|
64
|
Impact of MCP-1-2518-G allele on the HIV-1 disease of children in the United States.
|
AIDS
|
2006
|
0.86
|
|
65
|
The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2013
|
0.85
|
|
66
|
Insulin-like growth factor-1 and lean body mass in HIV-infected children.
|
J Acquir Immune Defic Syndr
|
2008
|
0.85
|
|
67
|
A sequential design to estimate sensitivity and specificity of a diagnostic or screening test.
|
Stat Med
|
2006
|
0.85
|
|
68
|
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
|
J Clin Microbiol
|
2009
|
0.85
|
|
69
|
Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States.
|
J Acquir Immune Defic Syndr
|
2004
|
0.84
|
|
70
|
Dynamic calibration of pharmacokinetic parameters in dose-finding studies.
|
Biostatistics
|
2010
|
0.83
|
|
71
|
A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children.
|
Biometrics
|
2008
|
0.82
|
|
72
|
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.
|
Antimicrob Agents Chemother
|
2007
|
0.81
|
|
73
|
High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.
|
J Acquir Immune Defic Syndr
|
2013
|
0.81
|
|
74
|
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
|
Pediatr Infect Dis J
|
2005
|
0.81
|
|
75
|
Sexual behavior, psychosocial and knowledge differences between consistent, inconsistent and non-users of condoms: a study of female bar and hotel workers in Moshi, Tanzania.
|
AIDS Behav
|
2006
|
0.81
|
|
76
|
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
|
J Acquir Immune Defic Syndr
|
2014
|
0.80
|
|
77
|
Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.
|
Pediatrics
|
2002
|
0.79
|
|
78
|
Lack of protective effects of interleukin-4 -589-C/T polymorphism against HIV-1-related disease progression and central nervous system impairment, in children.
|
J Infect Dis
|
2004
|
0.79
|
|
79
|
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.
|
J Acquir Immune Defic Syndr
|
2011
|
0.79
|
|
80
|
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.
|
Clin Infect Dis
|
2013
|
0.79
|
|
81
|
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
|
AIDS
|
2014
|
0.79
|
|
82
|
Vitamin D insufficiency in HIV-infected pregnant women receiving antiretroviral therapy is not associated with morbidity, mortality or growth impairment in their uninfected infants in Botswana.
|
Pediatr Infect Dis J
|
2014
|
0.79
|
|
83
|
Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virus.
|
J Pediatr Gastroenterol Nutr
|
2009
|
0.78
|
|
84
|
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
|
BMC Infect Dis
|
2014
|
0.78
|
|
85
|
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
|
J Acquir Immune Defic Syndr
|
2010
|
0.77
|
|
86
|
Arterial stiffness, oxidative stress, and smoke exposure in wildland firefighters.
|
Am J Ind Med
|
2014
|
0.76
|
|
87
|
Exposures and cross-shift lung function declines in wildland firefighters.
|
J Occup Environ Hyg
|
2014
|
0.76
|
|
88
|
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.
|
HIV Clin Trials
|
2015
|
0.75
|
|
89
|
Factors affecting timing of antiretroviral treatment initiation based on monitoring CD4 counts.
|
J Acquir Immune Defic Syndr
|
2012
|
0.75
|
|
90
|
Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.
|
PLoS One
|
2013
|
0.75
|
|
91
|
Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1.
|
AIDS
|
2017
|
0.75
|
|
92
|
High hsCRP is associated with reduced lung function in structural firefighters.
|
Am J Ind Med
|
2013
|
0.75
|
|
93
|
Method for modeling radiative transport in luminescent particulate media.
|
Appl Opt
|
2016
|
0.75
|